Literature DB >> 4055544

The penetration of ceftriaxone into synovial fluid of the inflamed joint.

J R Morgan, A Paull, M O'Sullivan, B D Williams.   

Abstract

Fifteen patients with acute exacerbation of rheumatoid arthritis each received a 1 g bolus intravenous injection of ceftriaxone. Serum and synovial fluid was sampled at intervals between 1 h and 24 h later and assayed for ceftriaxone. Synovial fluid leucocyte counts and albumin content were measured concomitantly. Detectable levels of ceftriaxone were found in synovial fluid and serum 24 h after injection. Synovial fluid ceftriaxone concentration ranged between 66% and 100% of the concomitant serum levels. No correlation was observed between synovial fluid ceftriaxone concentration and synovial fluid leucocyte count and albumin concentration.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4055544     DOI: 10.1093/jac/16.3.367

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  6 in total

Review 1.  Pharmacokinetic optimisation of the treatment of septic arthritis.

Authors:  K A Hamed; J Y Tam; C G Prober
Journal:  Clin Pharmacokinet       Date:  1996-08       Impact factor: 6.447

Review 2.  Ceftriaxone. A reappraisal of its antibacterial activity and pharmacokinetic properties, and an update on its therapeutic use with particular reference to once-daily administration.

Authors:  R N Brogden; A Ward
Journal:  Drugs       Date:  1988-06       Impact factor: 9.546

3.  In vitro and in vivo susceptibility of the Lyme disease spirochete, Borrelia burgdorferi, to four antimicrobial agents.

Authors:  R C Johnson; C Kodner; M Russell
Journal:  Antimicrob Agents Chemother       Date:  1987-02       Impact factor: 5.191

Review 4.  Management of infections due to antibiotic-resistant Streptococcus pneumoniae.

Authors:  S L Kaplan; E O Mason
Journal:  Clin Microbiol Rev       Date:  1998-10       Impact factor: 26.132

Review 5.  Clinical pharmacokinetics of ceftriaxone.

Authors:  J H Yuk; C H Nightingale; R Quintiliani
Journal:  Clin Pharmacokinet       Date:  1989-10       Impact factor: 6.447

6.  In vitro susceptibilities of Borrelia burgdorferi to five oral cephalosporins and ceftriaxone.

Authors:  W A Agger; S M Callister; D A Jobe
Journal:  Antimicrob Agents Chemother       Date:  1992-08       Impact factor: 5.191

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.